Pharmaceutical online advertising has the highest viewability rates of any industry, according to a study by comScore, Inc.
Pharmaceutical online advertising has the highest viewability rates of any industry, according to a study by comScore, Inc. Survey data from the eighth annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry also shows that online direct-to-consumer (DTC) marketing continues to increase conversion among patients and prospects.
According to the study, which included 163 pharmaceutical studies, site visitation to a branded pharmaceutical site continues to provide sizeable lifts in both brand awareness and favorability. Health marketers continue to use digital channels to reach consumers, and anywhere from three to seven billion display ads are delivered in the drugs and medication sector each month.
The viewability of an ad - the ability for an ad to actually be seen by a consumer - largely impacts the effectiveness of an advertising campaign. Out of the ten industries comScore benchmarked, pharmaceutical advertising impressions had the highest viewability rates.
“Our research shows that regardless of how condition sufferers get to the site, that visit has a significant influence in those patients seeking treatment,” said John Mangano, vice president for comScore Health Solutions. “Marketers should also take note of what devices consumers are using to engage with health-related content… Understanding how to reach consumers effectively through fast-emerging platforms such as mobile will help companies create better marketing and content strategies to connect with both prospects and patients alike.”
More information can be found here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.